Coumarin-induced acute cytolytic hepatitis. Two cases;Hepatite aigue cytolytique a la coumarine. Deux cas

Gastroenterologie Clinique et Biologique

Volumn 21, Issue 3, 1997, Pages 223-225

  Koch, Stéphane ^a,c   Beurton, Isabelle ^a   Bresson Hadni, Solange ^a   Monnot, Bénédicte ^a   Hrusovsky, Stéfan ^a   Becker, Marie Claude ^a   Vanlemmens, Claire ^a   Carbillet, Jean Pierre ^b   Miguet, Jean Philippe ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b UFR des Sciences Med et Pharmaceut   (France)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

acute cytolytic hepatitis; coumarin; diarrhea; drug induced hepatitis

Indexed keywords

COUMARIN; ANTICOAGULANT AGENT; COUMARIN DERIVATIVE;

ACUTE HEPATITIS; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG INDUCED DISEASE; DRUG RECHALLENGE; FEMALE; HUMAN; LYMPHEDEMA; RELAPSE; ACUTE DISEASE; MIDDLE AGED; REVIEW; TOXIC HEPATITIS; VEIN INSUFFICIENCY;

ACUTE DISEASE; ADULT; ANTICOAGULANTS; COUMARINS; FEMALE; HEPATITIS, TOXIC; HUMANS; MIDDLE AGED; VENOUS INSUFFICIENCY;

EID: 0030926959     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Casley-Smith JR, Morgan RG, Piller NB. Treatment of lymphedema of the arms and legs with 5,6-benzo-alpha-pyrone. N Engl J Med 1993;329:1158-63.
2. Casley-Smith JR, Wang CT, Casley-Smith JR. Reduction of filaritic lymphoedema and elephantiasis with 5,6 benzo-alpha-pyrone (coumarin). Br Med J 1993;307:1034-41.
3. Tseng A, Synder J, Lee W. Prevention of tumorigenesis of inductible EJ-ras oncogene-containing rat-1 cells with drugs that interact with the poly (ADP-ribose) polymerase system. Proceedings of the American Association for Cancer Research. Baltimore: American Association for Cancer Research, 1986;27:145.
4. Conley D, Marscall ME. Effects of coumarin on human tumour cell growth and cell cycle analysis in vitro. Proceedings of the American Association for Cancer Research. Baltimore: American Association for Cancer Research, 1987;28:63.
5. Wattenberg LW, Tam LK, Fladmore AV. Inhibition of chemical carcinogen-induced neoplasia by coumarins and alpha-angelicolactone. Cancer Res 1979;39:1651-4.
6. Feuer G, Kellen JA, Kovacs K. Suppression of 7,12-dimethylbenz(a)anthracene-induced breast carcinoma by coumarin in the rat. Oncology 1976;33:35-9.
7. e mise à jour du fichier bibliographique des atteintes hépatique et des médicaments responsables. Gastroenterol Clin Biol 1996;20:744-79.
8. Stricker BHCH. Drug-indueed hepatic injury. 2nd ed. Amsterdam: Elsevier, 1992.
9. Faursehou P. Toxic hepatitis due to benzo-pyrone. Hum Toxicol 1982;1:149-50.
10. Casley-Smilh JR, Casley-Smith JR. Frequency of coumarin hepatotoxicity. Med J Austr 1995;162:391.
11. Basset ML, Dahistrom JE. Liver failure while taking coumarin. Med J Austr 1995;163:106.
12. Beinssen APA. Possible coumarin hepatotoxieity. Med J Austr 1994;161:725.
13. Morrison L, Welsky P. Side-effect of coumarin. Postgrad Med J 1995;71:701-2.
14. Sgro C, Taque R, Zoll A, Hillon P. Cytolytic hepatitis with a venotonic drug. J Hepatol 1995;22:251.
15. Larrey D, Hépatites aiguës médicamenteuses. Imputabilité et aspects cliniques. Gastroenterol Clin Biol 1995;19:B57-62.
16. Danan G. Définitions et crifères d'imputabilité des atteintes hépatiques aiguës médicamenteuses. Conclusions d'une réunion internationale de consensus. Gastroenterol Clin Biol 1993;17:H18-21.
17. Cox D. The rarity of liver toxicity in patients treated with coumarin (1,2-benzo-alpha-pyrone). Hum Toxicol 1989;8:501-6.
18. Shilling WH, Cramton RF, Longland RG. Metabolism of coumarin in man. Nature 1969;221:664-6.
19. Hazelton LW, Tusing TW, Zeitlin BR, Theissen R, Murer HK. Toxicity of coumarin. J Pharm Exp Ther 1956;116:248-58.